Literature DB >> 17939021

Resistance to apoptosis and expansion of regulatory T cells in relation to the detection of circulating tumor cells in patients with metastatic epithelial cancer.

Stefanie Stanzer1, Nadia Dandachi, Marija Balic, Margit Resel, Hellmut Samonigg, Thomas Bauernhofer.   

Abstract

Regulatory T cells may be crucial in the development of T cell tolerance to malignancies and contribute to immune dysfunctions. We investigated the percentage, activity, and onset of apoptosis of T cell subpopulations by multicolor flow cytometry in metastatic epithelial cancer patients compared to normal controls. Furthermore, a possible relationship between the presence of circulating tumor cells detected by immunocytochemistry and immune cell abnormalities was evaluated. Our study demonstrated a significantly elevated proportion of regulatory T cells in cancer patients (p < 0.001). In contrast to all other T cell subpopulations, regulatory T cells showed comparable Annexin V-binding characteristics in patients and normal controls. No relationship between the detection of circulating tumor cells and immune dysfunction was observed. These results indicate that cancer patients have a higher number of regulatory T cells with resistance to apoptotic stimuli partly responsible for immune dysfunctions as often observed in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17939021     DOI: 10.1007/s10875-007-9139-2

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  32 in total

1.  In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death.

Authors:  Benedikt Fritzsching; Nina Oberle; Nadine Eberhardt; Sabine Quick; Jürgen Haas; Brigitte Wildemann; Peter H Krammer; Elisabeth Suri-Payer
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

2.  CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.

Authors:  Koji Kono; Hiromichi Kawaida; Akihiro Takahashi; Hidemitsu Sugai; Kosaku Mimura; Naoto Miyagawa; Hideo Omata; Hideki Fujii
Journal:  Cancer Immunol Immunother       Date:  2005-11-23       Impact factor: 6.968

3.  Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.

Authors:  Jeong Whun Kim; Eva Wieckowski; Douglas D Taylor; Torsten E Reichert; Simon Watkins; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

4.  Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer.

Authors:  Thomas Bauernhofer; Iris Kuss; Brent Henderson; Andrew S Baum; Theresa L Whiteside
Journal:  Eur J Immunol       Date:  2003-01       Impact factor: 5.532

5.  Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death.

Authors:  Benedikt Fritzsching; Nina Oberle; Eva Pauly; Robert Geffers; Jan Buer; Johannes Poschl; Peter Krammer; Otwin Linderkamp; Elisabeth Suri-Payer
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

Review 6.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

7.  CD4+ CD25high regulatory T cells reduce T cell transendothelial migration in cancer patients.

Authors:  Karin Enarsson; B Samuel Lundin; Erik Johnsson; Thomas Brezicka; Marianne Quiding-Järbrink
Journal:  Eur J Immunol       Date:  2007-01       Impact factor: 5.532

8.  Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer.

Authors:  Thomas Bauernhofer; Sabine Zenahlik; Günter Hofmann; Marija Balic; Margit Resel; Renate Pirchmoser; Peter Regitnig; Peter Ambros; Nadia Dandachi; Hellmut Samonigg
Journal:  Oncol Rep       Date:  2005-02       Impact factor: 3.906

9.  Role of prolactin receptor and CD25 in protection of circulating T lymphocytes from apoptosis in patients with breast cancer.

Authors:  T Bauernhofer; I Kuss; U Friebe-Hoffmann; A S Baum; G Dworacki; B K Vonderhaar; T L Whiteside
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

10.  TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells.

Authors:  Song Guo Zheng; Ju Hua Wang; William Stohl; Kyoung Soo Kim; J Dixon Gray; David A Horwitz
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

View more
  8 in total

1.  Impaired thymic export and increased apoptosis account for regulatory T cell defects in patients with non-ST segment elevation acute coronary syndrome.

Authors:  Wen-cai Zhang; Jun Wang; Yan-wen Shu; Ting-ting Tang; Zheng-feng Zhu; Ni Xia; Shao-fang Nie; Juan Liu; Su-feng Zhou; Jing-jing Li; Hong Xiao; Jing Yuan; Meng-yang Liao; Long-xian Cheng; Yu-hua Liao; Xiang Cheng
Journal:  J Biol Chem       Date:  2012-08-07       Impact factor: 5.157

Review 2.  Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.

Authors:  Malte Mohme; Sabine Riethdorf; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2016-09-20       Impact factor: 66.675

3.  Immunological milieu in the peritoneal cavity at laparotomy for gastric cancer.

Authors:  Akira Yoneda; Shinichiro Ito; Seiya Susumu; Mitsutoshi Matsuo; Ken Taniguchi; Yoshitsugu Tajima; Susumu Eguchi; Takashi Kanematsu; Yasuhiro Nagata
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

4.  Impaired thymic export and apoptosis contribute to regulatory T-cell defects in patients with chronic heart failure.

Authors:  Ting-Ting Tang; Zheng-Feng Zhu; Jun Wang; Wen-Cai Zhang; Xin Tu; Hong Xiao; Xin-Ling Du; Jia-Hong Xia; Nian-Guo Dong; Wei Su; Ni Xia; Xin-Xin Yan; Xing-Xing Yan; Shao-Fang Nie; Juan Liu; Su-Feng Zhou; Rui Yao; Jiang-Jiao Xie; Harish Jevallee; Xiang Wang; Meng-Yang Liao; Guo-Ping Shi; Michael Fu; Yu-Hua Liao; Xiang Cheng
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

5.  A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies.

Authors:  Elena Muraro; Debora Martorelli; Elisa Turchet; Gianmaria Miolo; Simona Scalone; Elisa Comaro; Renato Talamini; Katy Mastorci; Davide Lombardi; Tiziana Perin; Antonino Carbone; Andrea Veronesi; Diana Crivellari; Riccardo Dolcetti
Journal:  Breast Cancer Res       Date:  2011       Impact factor: 6.466

6.  Clinical significance of circulating immune cells in left- and right-sided colon cancer.

Authors:  Jiabo Di; Meng Zhuang; Hong Yang; Beihai Jiang; Zaozao Wang; Xiangqian Su
Journal:  PeerJ       Date:  2017-12-08       Impact factor: 2.984

7.  Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.

Authors:  Herschel Wallen; John A Thompson; J Zachary Reilly; Rebecca M Rodmyre; Jianhong Cao; Cassian Yee
Journal:  PLoS One       Date:  2009-03-09       Impact factor: 3.240

Review 8.  The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy.

Authors:  Kevin Leone; Cristina Poggiana; Rita Zamarchi
Journal:  Diagnostics (Basel)       Date:  2018-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.